Table 3.
Open pediatric trials using CD19 CAR T-cells (as of April 2018)
| Title | Sponsor | Clinical trial number | Phase |
|---|---|---|---|
| Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy | University of Pennsylvania | NCT02374333 | I |
| Leukapheresis for CAR Therapy Manufacturing | National Cancer Institute (NCI) | NCT03226704 | n.a. |
| In Vitro Expanded Allogeneic Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies | Memorial Sloan Kettering Cancer Center | NCT01430390 | I |
| Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post-HSCT (CARCIK) | Fondazione Matilde Tettamanti Menotti De Marchi Onlus (Italy) | NCT03389035 | I/II |
| CD22 Redirected Autologous T Cells for ALL | University of Pennsylvania | NCT02650414 | I |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T-cells Targeting CD19 and CD22 | Chinese PLA General Hospital | NCT03185494 | I/II |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T-cells Targeting CD19 and CD20 | Chinese PLA General Hospital | NCT03097770 | I/II |
| Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | University of Pennsylvania | NCT02906371 | I |
| Sequential Treatment With CD20/CD22/CD10-CART After CD19−CART Treatment Base on MRD in Relapsed/Refractory B-ALL | Zhujiang Hospital (China) | NCT03407859 | I |
| CD19 CAR and PD-1 Knockout Engineered T Cells for CD19−Positive Malignant B-cell Derived Leukemia and Lymphoma | Third Military Medical University (China) | NCT03298828 | I |
| CD19/22 CAR T-cells (AUTO3) for the Treatment of B Cell ALL (AMELIA) | Autolus Limited (London) | NCT03289455 | I/II |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | National Cancer Institute (NCI) | NCT03448393 | I |
| CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia | Stanford University | NCT03241940 | I |
| Sequential Infusion of Anti-CD19 and Anti-CD20 CAR T-Cells Against Relapsed and Refractory B-cell Lymphoma | Shanghai Longyao Biotechnology Inc., Ltd. (China) | NCT03207178 | I/II |
| Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma | Pinze Lifetechnology Co. Ltd. (China) | NCT03281551 | I |
| CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | Shanghai Unicar-Therapy Biomedicine Technology Co., Ltd. (China) | NCT03064269 | I |
| CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | Federal Research Institute of Pediatric Hematology, Oncology and Immunology (Russia) | NCT03467256 | I |
| CD19 CAR T-Cells for Patients With Relapse and Refractory CD19+ B-ALL | Henan Cancer Hospital (China) | NCT03263208 | I/II |
| CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Hematological Malignancies | University College, London | NCT02443831 | I |
| A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | The First People’s Hospital of Yunnan (China) | NCT02968472 | I |
| CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | Wuhan Sian Medical Technology Co., Ltd. (China) | NCT02965092 | I |
| CART-19 Cells for R/R B-ALL (CCFRRBA) | Fujian Medical University (China) | NCT03391739 | II/III |
| T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | Sheba Medical Center (Israel) | NCT02772198 | I/II |
| Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | Wuhan Sian Medical Technology Co., Ltd. (China) | NCT03366350 | I/II |
| Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | Wuhan Sian Medical Technology Co., Ltd. (China) | NCT03366324 | I |
| Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | Beijing Sanwater Biological Technology Co., Ltd. (China) | NCT02810223 | I |
| A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+ B-ALL | Cellular Biomedicine Group Ltd. | NCT03018093 | I |
| T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | Memorial Sloan Kettering Cancer Center | NCT01860937 | I |
| Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (TBI-1501) | Takara Bio Inc. (Japan) | NCT03155191 | I/II |
| Activated T-Cells Expressing 2nd or 3rd Generation CD19−Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) | Baylor College of Medicine | NCT01853631 | I |
| A Study of Anti-CD19 CAR T-Cell Immunotherapy for Refractory/Relapsed B Cell Malignancies | Second Affiliated Hospital of Guangzhou Medical University (China) | NCT03191773 | I/II |
| A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies | Shenzhen Geno-Immune Medical Institute (China) | NCT03050190 | I/II |
| A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia | Seattle Children’s Hospital | NCT01683279 | I |
| CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non-Hodgkin’s Lymphoma, ALL & CLL (CRETI-NH) | Baylor College of Medicine | NCT00586391 | I |
| Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | First Affiliated Hospital of Wenzhou Medical University (China) | NCT03110640 | I |
| Combination CAR T-Cell Therapy Targeting Hematological Malignancies | Shenzhen Geno-Immune Medical Institute (China) | NCT03125577 | I/II |
| Dose Escalation Study of UCART19 in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia (CALM) | Servier (France) | NCT02746952 | I |
| Competitive Transfer of αCD19−TCRz-CD28 and αCD19−TCRz-CD137 CAR T-Cells for B-cell Leukemia/Lymphoma (MatchCART) | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | NCT02685670 | I/II |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19) | Chinese PLA General Hospital | NCT01864889 | I |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | Shenzhen Institute for Innovation and Translational Medicine (China) | NCT03076437 | I |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | Shenzhen Second People’s Hospital (China) | NCT02456350 | I |
| Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL) | Servier (France) | NCT02808442 | I |
Abbreviations: HSCT, hematopoietic stem cell transplantation; n.a., not applicable.